Elevated kallikrein activity in plasma from stable liver transplant recipients

International Immunopharmacology

Volumn 2, Issue 12, 2002, Pages 1667-1680

  Hayashi, Joichiro ^a   Salomon, Daniel R ^b   Hugli, Tony E ^a  

^a LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Complement activation; Liver transplantation; Plasma kallikrein; Plasma peptidase activity

Indexed keywords

ANILIDE; CHROMOGENIC SUBSTRATE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C4; DEXTRO PHENYLALANYLPHENYLALANYLARGINYL CHLOROMETHYL KETONE; EDETIC ACID; HIRUDIN; KALLIKREIN; KALLIKREIN INHIBITOR; PLASMA PROTEIN; PROTEINASE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C4A; SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GRAFT REJECTION; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; RECURRENT INFECTION; BLOOD; DRUG ANTAGONISM; FEMALE; GEL CHROMATOGRAPHY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; CHROMATOGRAPHY, GEL; COMPLEMENT C4; COMPLEMENT C4A; FEMALE; GRAFT REJECTION; HUMANS; KALLIKREINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SERINE PROTEINASE INHIBITORS;

EID: 0036842151     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00144-3     Document Type: Article

References (43)

1. Pfeifer P.H., Kawahara M., Hugli T.E. Possible mechanism for in vitro complement (C) activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin. Chem. 45:1999;1190-1199.
2. Ikari N., Sakai Y., Hitomi Y., Fujii S. New synthetic inhibitor to the alternative complement pathway. Immunology. 49:1983;685-691.
3. Hitomi Y., Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int. Arch. Allergy Appl. Immunol. 69:1982;262-267.
4. Pfeifer P.H., Brems J.J., Brunson M., Hugli T.E. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology. 46:2000;163-174.
5. Moon K.E., Gorski J.P., Hugli T.E. Complete primary structure of human C4a anaphylatoxin. J. Biol. Chem. 256:1981;8685-8692.
6. Petry F., Loos M. Bacteria and complement. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;375-391 Marcel Dekker, New York.
7. Cooper N.R. Complement and viruses. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;393-407 Marcel Dekker, New York.
8. Schenkein H.A. The role of complement in periodontal diseases. Crit. Rev. Oral Biol. Med. 2:1991;65-81.
9. Franco A.G., Schur P.H. Hypocomplementemia in rheumatoid arthritis. Arthritis Rheum. 14:1971;231-238.
10. Buyon J.P., Tamerius J., Ordorica S., Young B., Abramson S.B. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 35:1992;55-61.
11. Moxley G., Ruddy S. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis Rheum. 30:1987;1097-1104.
12. Atkinson J.P. Complement activation and complement receptors in systemic lupus erythematosus. Semin. Immunol. Pathol. 9:1986;179-194.
13. Townes A.S., Stewart C.R. Estimations of the second component and third component complex of complement in the serum of patients with systemic lupus erythematosus. Bull. Johns Hopkins Hosp. 117:1965;348-362.
14. Hack C.E., Nuijens J.H., Felt-Bersma R.J.F.et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. Am. J. Med. 86:1989;20-26.
15. Heideman M., Hugli T.E. Anaphylatoxin generation in multisystem organ failure. J. Trauma. 24:1984;1038-1043.
16. Chenoweth D.E., Cooper S.W., Hugli T.E., Stewart R.W., Blackstone E.H., Kirklin J.W. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N. Engl. J. Med. 304:1981;497-503.
17. Craddock P.R., Fehr J., Brigham K.L., Kronenberg R.S., Jacob H.S. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N. Engl. J. Med. 296:1977;769-774.
18. Nusbacher J., Rosenfeld S.I., MacPherson J.L., Thiem P.A., Leddy J.P. Nylon fiber leukapheresis: associated complement component changes and granulocytopenia. Blood. 51:1978;359-365.
19. Hammerschmidt D.E., Craddock P.R., McCullough J., Kronenberg R.S., Dalmasso A.P., Jacob H.S. Complement activation and pulmonary leukostasis during nylon fiber filtration leukapheresis. Blood. 51:1978;721-730.
20. Kirschfink M., Wienert T., Rother K., Pomer S. Complement activation in renal allograft recipients. Transplant. Proc. 24:1992;2556-2557.
21. Ronholm E., Tomasdottir H., Runeborg J.et al. Complement system activation during orthotopic liver transplantation in man. Transplantation. 57:1994;1594-1597.
22. Scholz T., Backman L., Mathisen O.et al. Activation of the plasma contact system and hemodynamic changes after graft revascularization in liver transplantation. Transplantation. 60:1995;36-40.
23. Hayashi J., Hugli T.E. Kallikrein-like activity associated with α-2-macroglobulin (α-2-M) in plasma from liver transplant recipients [abstract]. Protein Sci. 9:2000;462-T.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
25. Ouchterlony O., Nilsson L.-A. Immunodiffusion and immunoelectrophoesis. Weir D.M., Herzenberg L.A., Blackwell C. Handbook of Experimental Immunology. 1986;32.1-32.5 Blackwell, Oxford.
26. Violi F., Ferro D., Basili S.et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J. Investig. Med. 43:1995;550-554.
27. 2-Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood. 77:1991;2660-2667.
28. Veloso D., Silver L., Hahn S., Colman R. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekillkrein by factor XIIa on a surface. Blood. 70:1987;1053-1062.
29. Budzko D.B., Bokisch V.A., Muller-Eberhard H.J. A fragment of the third component of human complement with anaphylatoxin activity. Biochemistry. 10:1971;1166-1172.
30. Patrick R.A., Taubman S.B., Lepow I.H. Cleavage of the fourth component of human complement (C4) by activated C1s. Immunochemistry. 7:1970;217-225.
31. Reid K.B.M. C1q and mannose-binding lectin. Volanakis J., Frank M. The Human Complement System in Health and Disease. 1998;33-48 Marcel Dekker, New York.
32. Renaux J.-L., Thomas M., Crost T., Loughraieb N., Vantard G. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney Int. 55:1999;1097-1103.
33. 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 260:1985;4257-4263.
34. Teitel J.M., Bauer K.A., Lau H.K., Rosenberg R.D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F1/F1+2 fragment and thrombin-antithrombin complex. Blood. 59:1982;1086-1097.
35. Schapira M., Scott C.F., Colman R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69:1982;462-468.
36. Motta G., Rojkjaer R., Hasan A.A.K., Cines D.B., Schmaier A.H. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood. 91:1998;516-528.
37. Love R.A., Parge H.E., Wickersham J.A.et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 87:1996;331-342.
38. Drouet C., Bouillet L., Csoopaki F., Colomb M.G. Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor. FEBS Lett. 458:1999;415-418.
39. Björk I., Jackson C.M., Jornvall H., Lavine K.K., Nordling K., Salsgiver W.J. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXA and thrombin. J. Biol. Chem. 257:1982;2406-2411.
40. van der Graaf F., Koedam J.A., Bouma B.N. Inactivation of kallikrein in human plasma. J. Clin. Invest. 71:1983;149-158.
41. Ellis V., Scully M., MacGregor I., Kakkar V. Inhibition of human factor Xa by various plasma protease inhibitors. Biochim. Biophys. Acta. 701:1982;24-31.
42. 1-proteinase inhibitor in human plasma. J. Biol. Chem. 259:1984;6890-6895.
43. 2-macroglobulin. Biochemistry. 26:1987;5932-5937.